At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
IBB iShares Biotechnology ETF
Pre-Mkt 08-05 04:59:08 EDT
190.15
+4.24
+2.28%
盘前191.44
+1.29+0.68%
04:00 EDT
High190.20Low186.03Vol1.15M
Open187.41D1 Closing185.91Amplitude2.25%
Mkt Cap9.41BTradable Cap9.41BTotal Shares49.50M
T/O216.38MT/O Rate2.32%Tradable Shares49.50M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Street View: Gilead's HIV Strength Outshines Long-Term Competitive Worries
Reuters  ·  12 minutes ago
Street View: Gilead's HIV Strength Outshines Long-Term Competitive Worries
Sino Biopharmaceutical Stock Slips 1.2% in Hong Kong
Dow Jones  ·  28 minutes ago
Sino Biopharmaceutical Stock Slips 1.2% in Hong Kong
Street View: Amgen Builds Momentum with Blockbusters, Biosimilars and a Pipeline in Waiting
Reuters  ·  35 minutes ago
Street View: Amgen Builds Momentum with Blockbusters, Biosimilars and a Pipeline in Waiting
Amgen Inc : Morgan Stanley Raises Target Price to $351 from $333
THOMSON REUTERS  ·  14:30
Amgen Inc : Morgan Stanley Raises Target Price to $351 from $333
Switzerland's Sandoz H1 Net Sales Rise on Biosimilar Growth
Reuters  ·  13:08
Switzerland's Sandoz H1 Net Sales Rise on Biosimilar Growth
Radiopharm Theranostics Lifts Cap on Securities Purchase Plan to AUD10 Million
TIPRANKS  ·  12:02
Radiopharm Theranostics Lifts Cap on Securities Purchase Plan to AUD10 Million
Amgen Inc : Oppenheimer Raises Target Price to $450 from $400
THOMSON REUTERS  ·  11:10
Amgen Inc : Oppenheimer Raises Target Price to $450 from $400
Actinogen Medical Seeks ASX Quotation for 3.5 Million Incentive Shares
TIPRANKS  ·  10:57
Actinogen Medical Seeks ASX Quotation for 3.5 Million Incentive Shares
Gilead : Truist Securities Cuts Target Price to $150 from $156
THOMSON REUTERS  ·  10:45
Gilead : Truist Securities Cuts Target Price to $150 from $156
Gilead Corrects Q2 2026 Europe Odefsey Sales to $58 Million
Reuters  ·  09:47
Gilead Corrects Q2 2026 Europe Odefsey Sales to $58 Million
Dow Jones Top Company Headlines at 7 PM ET: SpaceX Revenue Could Reach $1 Trillion, Elon Musk Says | Paramount's ...
Dow Jones  ·  07:00
Dow Jones Top Company Headlines at 7 PM ET: SpaceX Revenue Could Reach $1 Trillion, Elon Musk Says | Paramount's ...
Gilead Forecasts FY26 Yeztugo Revenue at About $1 Billion
Reuters  ·  06:11
Gilead Forecasts FY26 Yeztugo Revenue at About $1 Billion
Gilead CEO Daniel O’Day Sells 15,000 Common Shares Worth $1.96 Million
Reuters  ·  06:11
Gilead CEO Daniel O’Day Sells 15,000 Common Shares Worth $1.96 Million
Gilead Says Q2 2026 Revenue Growth is Driven by Biktarvy, Descovy and Yeztugo Demand, Pricing Gains
Reuters  ·  05:45
Gilead Says Q2 2026 Revenue Growth is Driven by Biktarvy, Descovy and Yeztugo Demand, Pricing Gains
Amgen Announces Availability of Q2 2026 Earnings Report Release
Reuters  ·  05:41
Amgen Announces Availability of Q2 2026 Earnings Report Release
Amgen's Strong Second Quarter Drug Sales Drive Upward Forecast Revision and Early-Stage Weight Loss Drug Termination
Deep News  ·  05:21
Amgen's Strong Second Quarter Drug Sales Drive Upward Forecast Revision and Early-Stage Weight Loss Drug Termination
Gilead Sciences Posts Net Loss as R&D Costs from Acquisitions Weigh on HIV Drug Revenue Growth
Deep News  ·  05:10
Gilead Sciences Posts Net Loss as R&D Costs from Acquisitions Weigh on HIV Drug Revenue Growth
Gilead Sciences, Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  05:01
Gilead Sciences, Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
Amgen Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  05:01
Amgen Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
Amgen Exec Says Continues to Expect Capital Expenditures of About $2.6 Billion in 2026 to Scale Manufacturing Capacity, Including for Maritide's Launch
THOMSON REUTERS  ·  04:59
Amgen Exec Says Continues to Expect Capital Expenditures of About $2.6 Billion in 2026 to Scale Manufacturing Capacity, Including for Maritide's Launch

Introduction

Company Name.
iShares Biotechnology ETF
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. It is non-diversified.
Issue price:
--